Celgene Corp. (CELG)

CELG (NASDAQ:Biotechnology) EQUITY
$90.35
pos +0.20
+0.22%
Today's Range: 89.24 - 90.97 | CELG Avg Daily Volume: 6,275,700
Last Update: 08/17/18 - 4:55 PM EDT
Volume: 0
YTD Performance: -13.41%
Open: $0.00
Previous Close: $90.15
52 Week Range: $74.13 - $147.17
Oustanding Shares: 703,363,000
Market Cap: 63,408,171,875
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 13 13 13 14
Moderate Buy 1 1 1 1
Hold 10 10 12 12
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.88 1.88 1.96 1.93
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 20.92
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
20.92 24.52 19.40
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
12.99% -29.17% -31.13%
GROWTH 12 Mo 3 Yr CAGR
Revenue 17.40 0.70 0.19
Net Income 46.69 0.50 0.14
EPS 46.19 0.50 0.15
Earnings for CELG:
EBITDA 3.65B
Revenue 12.82B
Average Earnings Estimates
Qtr (09/18) Qtr (12/18) FY (12/18) FY (12/19)
Average Estimate $1.99 $2.13 $7.64 $9.47
Number of Analysts 3 3 1 3
High Estimate $2.01 $2.15 $7.64 $9.61
Low Estimate $1.98 $2.12 $7.64 $9.27
Prior Year $1.78 $1.87 $6.84 $7.64
Growth Rate (Year over Year) 11.99% 14.08% 11.70% 23.91%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Bret Jensen

 | Aug 6, 2018 | 10:17 AM EDT
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
RMPIA
By

Guy Ortmann

 | Jul 30, 2018 | 3:16 PM EDT
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
RMPIA
By

Real Money

 | Jul 6, 2018 | 12:26 PM EDT
Investors might be finally recognizing the hidden value of the firms' drug research and development.
RMPIA
By

Bruce Kamich

 | Jul 6, 2018 | 11:17 AM EDT
With biotech names getting some attention this morning a quick review looks like a good idea.
RMPIA
By

Bruce Kamich

 | Jun 25, 2018 | 10:46 AM EDT
Charts suggest Celgene has put in a low for now.
RMPIA
By

Jim Cramer

 | Jun 18, 2018 | 2:08 PM EDT
Taking the measure of what's keeping the markets in the dumps.
RMPIA
By

Bruce Kamich

 | May 30, 2018 | 2:16 PM EDT
Here's our new strategy for the shares.
RMPIA
By

Timothy Collins

 | May 25, 2018 | 10:35 AM EDT
For the trade, I'm opting to use the iShares Nasdaq Biotechnology ETF.
RMPIA
By

Bret Jensen

 | May 4, 2018 | 9:02 AM EDT
The April Jobs report showed that 164,000 jobs were created last month. This is nearly 30,000 jobs less than the consensus. Unemployment rates tumbles to 3.9%, the first time under the 4% level in almost two decades.
RMPIA
By

Stephen Guilfoyle

 | May 4, 2018 | 7:50 AM EDT
The Chinese have something to lose here, and will not willingly surrender their position of superiority in trade.
Barrons.com noted significant insider purchases in the beat-up shares of Newell (NWL). ....

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by

COLUMNIST TWEETS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.